The Axial Company

Axial Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of gut-restricted small molecule therapeutics to treat central nervous system (CNS) disorders and other diseases. By targeting the gut-brain axis, the company aims to mitigate the effects of specific microbial metabolites that influence brain function and behavior. Their lead candidate, AB-2004, is currently being evaluated in Phase 2 clinical trials for the treatment of irritability associated with Autism Spectrum Disorder. Axial's approach leverages foundational research from the California Institute of Technology regarding the role of the microbiome in neurological health. The company is also developing programs for Parkinson's disease and oncology, focusing on small molecules that act locally in the gut to achieve systemic therapeutic effects.